{"id":493286,"date":"2021-05-13T16:04:31","date_gmt":"2021-05-13T20:04:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/brickell-biotech-reports-first-quarter-2021-financial-results-and-provides-corporate-update\/"},"modified":"2021-05-13T16:04:31","modified_gmt":"2021-05-13T20:04:31","slug":"brickell-biotech-reports-first-quarter-2021-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/brickell-biotech-reports-first-quarter-2021-financial-results-and-provides-corporate-update\/","title":{"rendered":"Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update"},"content":{"rendered":"
\n

\n Completed enrollment in Phase 3 pivotal Cardigan I study and exceeded 70% enrollment in Phase 3 pivotal Cardigan II study<\/em>
\n
\n – – –<\/em>
\n
\n Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected in Q4 2021<\/em>
\n
\n – – –<\/em>
\n
\n Presented results from Phase 3 open-label, long-term safety study of sofpironium bromide gel, 5% & 15% at AAD VMX 2021<\/em>\n <\/p>\n

BOULDER, Colo., May 13, 2021 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (\u201cBrickell\u201d or the \u201cCompany\u201d) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the first quarter ended March\u00a031, 2021 and provided a corporate update.<\/p>\n

\u201cThe beginning of 2021 has been a very productive period for the Brickell team, as we continue to execute against our development strategy for sofpironium bromide gel, 15% as a potential best-in-class treatment option for primary axillary hyperhidrosis,\u201d commented Robert Brown, Chief Executive Officer of Brickell. \u201cMost importantly, we continue to see patient enrollment in our Phase 3 pivotal clinical studies meet expectations, with enrollment completed last month in the Cardigan I study, and 70% enrollment surpassed in the Cardigan II study. As a result, we are on track to announce topline data from both studies in the fourth quarter of 2021. If these studies are successful, we expect to proceed towards an NDA submission to the U.S. FDA in 2022.\u201d<\/p>\n

Mr. Brown continued, \u201cIn April 2021, we were pleased to highlight data from the ARGYLE study, our Phase 3 open-label, long-term safety study of sofpironium bromide gel, as part of the late-breaking research program at the American Academy of Dermatology\u2019s Virtual Meeting Experience 2021. In this study, sofpironium bromide gel was generally well-tolerated with continued efficacy during 48 weeks in patients with primary axillary hyperhidrosis. These data further contribute to our understanding of the long-term use of sofpironium bromide gel as a potential novel treatment for the millions of patients suffering from this chronic and debilitating condition.\u201d<\/p>\n

\n Business and Recent Developments<\/strong>\n <\/p>\n